孟鲁司特钠联合糖皮质激素治疗儿童咳嗽变异型哮喘

Clinical observation of Montelukast and Glucocorticoid in children with cough variation asthma

目的评估应用孟鲁司特钠联合糖皮质激素对咳嗽变异性哮喘患儿的疗效。方法 67位被诊断为儿童咳嗽变异性哮喘的病例随机分为治疗组34例和对照组33例。治疗组使用孟鲁司特联合吸入糖皮质激素,而对照组仅使用吸入糖皮质激素。并观察两组呼吸峰流速(PEF),临床疗效,以及复发情况。结果治疗组临床疗效,呼吸峰流速(PEF),及复发率均优于对照组,组间比较差异具有统计学意义(P<0.05)。结论孟鲁司特联合糖皮质激素在咳嗽变异性哮喘患儿治疗中能提高有效率,减少复发,值得临床推广。

Objective To investigate the curative effect of combing montelukast with inhaled corticosteroids in treatment of children with CVA. Methods All the 67 examples diagnosed CVA were divided into the treatment group （ n = 34） and the control group （ n = 33 ） randomly. The children in treatment group were treated with montelukast Combined with inhaled Glucocorticoid, while those in the control group were treated only with inhaled Glucocorticoid. Observations were made on clinical therapeutic effects, the peak expiratory flow rate （PEFR） and the recurrence. Results Clinical efficacy the respiratory peak flow velocity （PEF） , and the recurrence rate were better in the treatment group than in the control group, and the difference between the two groups had statistical significance （ P 〈 0.05 ）. Conclusion Montelukast combined with Glucocortieoid in the treatment of childhood with cough variant asthma can boost clinical efficiency greatly, and reduce the recurrence. It＇s worth to be promoted and applied widely in clinical practice.